Cancer Therapy News and Research

RSS

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

Ahead of World Malaria Day (25 April), EU-funded researchers have discovered that drugs originally designed to inhibit the growth of cancer cells can also kill the parasite that causes malaria. They believe this discovery could open up a new strategy for combating this deadly disease, which, according to World Health Organisation statistics, infected around 225 million and killed nearly 800 000 people worldwide in 2009.

21 Apr 2011

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.

21 Apr 2011

Providing complete information about breast cancer treatment options often ends up overwhelming patients

Women who choose among different breast cancer treatment options make smarter choices when getting the information and making decisions in small doses rather than all at once, as is customary, a University of Michigan study found.

21 Apr 2011

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

ACE inhibitors, commonly used to control high blood pressure and heart failure in women, may be associated with an increased risk of recurrence in women who have had breast cancer, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

21 Apr 2011

Sialix announces blood test results for early detection and treatment of breast cancer

Sialix, Inc. a pioneer in glycobiology, today announced the results of a study it participated in with researchers at the University of California, San Diego School of Medicine that could have significant impact in the prediction, early detection and treatment of cancer in humans.

20 Apr 2011

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

ADVANCELL, an emerging Spanish biopharmaceutical company, has initiated a phase IIb clinical study of the Company's ATH008, for the treatment of the palmar-plantar erythrodysesthesia syndrome, also known as hand-foot syndrome, a painful side-effect of certain chemotherapies such as capecitabine and fluoropyrimidines.

20 Apr 2011

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Many of the newest weapons in the war on cancer come in the form of personalized therapies that can target specific changes in an individual's tumor. By disrupting molecular processes in tumor cells, these drugs can keep the tumor from growing and spreading. At the forefront of this work are Binghamton University researchers, Susan Bane, and Susannah Gal, who are deploying a new tool in their study of an enzyme called tubulin tyrosine ligase, or TTL.

20 Apr 2011

Antibodies to non-human sugar molecule may be useful for early detection of cancer

Researchers at the University of California, San Diego School of Medicine say antibodies to a non-human sugar molecule commonly found in people may be useful as a future biomarker for predicting cancer risk, for diagnosing cancer cases early and, in sufficient concentration, used as a treatment for suppressing tumor growth.

20 Apr 2011

Mount Sinai's new Dubin Breast Center to provide patients with seamless care

The new Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai opened today, bringing a range of multidisciplinary services under one roof and marking a great leap forward in care of breast cancer patients throughout the region.

19 Apr 2011

Bexion earns Biotech Innovation Award for new cancer treatment approach

Bexion Pharmaceuticals was named the Biotech Innovation Award winner at the Cincinnati USA Innovation Awards program sponsored by the Cincinnati Business Courier, the Cincinnati USA Regional Chamber and CincyTech.

19 Apr 2011

Radiologists to develop quantitative research tool that produces reliable numbers

The idea of probing the body's interior with radiation stretches back to experiments with X rays in the 1800s, but more than a century later, images taken with radiological scans still are not considered reliable enough to, for example, serve as the sole indicator of the efficacy of a cancer treatment.

16 Apr 2011

Novocure's NovoTTF-100A System receives FDA approval for GBM treatment

Novocure today announced that the U.S. Food and Drug Administration approved the NovoTTF-100A System for the treatment of adult patients with glioblastoma multiforme brain tumors, following tumor recurrence after receiving chemotherapy.

16 Apr 2011

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

The U.S. Food and Drug Administration recently approved the NovoTTF-100A System, a new device to treat adults with glioblastoma multiforme that recurs or progresses after receiving chemotherapy and radiation therapy.

15 Apr 2011

New approach links cancer cell metabolism with poor clinical outcome

Identifying gene mutations in cancer patients to predict clinical outcome has been the cornerstone of cancer research for nearly three decades, but now researchers at the Kimmel Cancer Center at Jefferson have invented a new approach that instead links cancer cell metabolism with poor clinical outcome. This approach can now be applied to virtually any type of human cancer cell.

15 Apr 2011

FEN1 enzyme might serve as anti-cancer therapy target

An enzyme essential for DNA replication and repair in humans works in a way that might be exploited as anti-cancer therapy, say researchers at The Scripps Research Institute and Lawrence Berkeley National Laboratory.

15 Apr 2011

Normal breast cells provide an innate defense mechanism against cancer

It is well known that the human body has a highly developed immune system to detect and destroy invading pathogens and tumor cells. Now, researchers at the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have shown that the body has a second line of defense against cancer - healthy cells.

15 Apr 2011

NRC, NCKU partner to develop cancer diagnostic and treatment technologies

A Taiwanese research team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University has partnered with a research group led by Dr. Dennis Whitefield from National Research Council of Canada to develop innovative cancer diagnostic and treatment technologies.

15 Apr 2011

EPO grants patent to OncoGenex OGX-427 for prostate cancer treatment

OncoGenex Pharmaceuticals, Inc., today announced that the European Patent Office has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers."

15 Apr 2011

The Wistar Institute, Advaxis enter research collaboration

Advaxis, Inc., the live, attenuated Listeria monocytogenes vaccine company, has entered into a research collaboration with the laboratory of Ellen Puré, Ph.D., professor/associate vice president for Academic Affairs at The Wistar Institute.

15 Apr 2011

Medicinal applications of fullerenes, filled with radioactive material

Fullerenes have attracted considerable attention in different fields of science since their discovery in 1985. Investigations of physical, chemical and biological properties of fullerenes have yielded promising information. It is inferred that size, hydrophobicity, three-dimensionality and electronic configurations make them an appealing subject in medicinal chemistry. Their unique carbon cage structure coupled with immense scope for derivatization make them a potential therapeutic agent.

13 Apr 2011

Cancer Therapy News and Research

Discovery of cancer drugs to kill malaria parasite could open up new strategies for treatment

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

Providing complete information about breast cancer treatment options often ends up overwhelming patients

Study finds ACE inhibitors linked to increased risk of recurrence in women who have had breast cancer

Sialix announces blood test results for early detection and treatment of breast cancer

Advancell initiates ATH008 phase IIb study for hand-foot syndrome

Researchers deploy new tool in study of tubulin tyrosine ligase in tumor growth

Antibodies to non-human sugar molecule may be useful for early detection of cancer

Mount Sinai's new Dubin Breast Center to provide patients with seamless care

Bexion earns Biotech Innovation Award for new cancer treatment approach

Radiologists to develop quantitative research tool that produces reliable numbers

Novocure's NovoTTF-100A System receives FDA approval for GBM treatment

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

New approach links cancer cell metabolism with poor clinical outcome

FEN1 enzyme might serve as anti-cancer therapy target

Normal breast cells provide an innate defense mechanism against cancer

NRC, NCKU partner to develop cancer diagnostic and treatment technologies

EPO grants patent to OncoGenex OGX-427 for prostate cancer treatment

The Wistar Institute, Advaxis enter research collaboration

Medicinal applications of fullerenes, filled with radioactive material

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News